{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:18:25Z","timestamp":1792498705402,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ando.2023.03.025","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T10:42:09Z","timestamp":1680000129000},"page":"401-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Doping with testosterone and androgenic\/anabolic steroids: Impact on health, screening tools and medical care"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9286-5631","authenticated-orcid":false,"given":"Jacques","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2023.03.025_bib0170","series-title":"Endotext [Internet]","article-title":"Performance enhancing hormone doping in sport","author":"Handelsman","year":"2020"},{"key":"10.1016\/j.ando.2023.03.025_bib0175","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/endrev\/bnab001","article-title":"Androgen misuse and abuse","volume":"42","author":"Handelsman","year":"2021","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2023.03.025_bib0180","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ucl.2022.07.008","article-title":"Androgenic steroids use and abuse: past, present, and future","volume":"49","author":"Thirumalai","year":"2022","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.ando.2023.03.025_bib0185","first-page":"534","article-title":"American college of sports medicine position stand on the use and abuse of anabolic-androgenic steroids in, sports","volume":"19","year":"1987","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.ando.2023.03.025_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199607043350101","article-title":"The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men","volume":"335","author":"Bhasin","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2023.03.025_bib0195","first-page":"2578","article-title":"Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans","volume":"82","author":"Young","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0200","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1210\/jcem.85.9.6811","article-title":"Effects of human recombinant luteinizing hormone and follicle-stimulating hormone in patients with acquired hypogonadotropic hypogonadism: study of Sertoli and Leydig cell secretions and interactions","volume":"85","author":"Young","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0205","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1210\/jc.2005-2569","article-title":"Clinical review: the rationale for banning human chorionic gonadotropin and estrogen blockers in sport","volume":"91","author":"Handelsman","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0210","doi-asserted-by":"crossref","first-page":"e3312","DOI":"10.1210\/clinem\/dgab169","article-title":"Compromised volumetric bone density and microarchitecture in men with congenital hypogonadotropic hypogonadism","volume":"106","author":"Ostertag","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0215","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.therap.2022.03.004","article-title":"Doping with aromatase inhibitors and oestrogen receptor modulators in steroid users: Analysis of a forum to identify dosages, durations and adverse drug reactions","volume":"77","author":"Rochoy","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.ando.2023.03.025_bib0220","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jat\/bkt041","article-title":"Determination of raloxifene in urine by liquid chromatography-tandem mass spectrometry for doping","volume":"37","author":"Chen","year":"2013","journal-title":"J Anal Toxicol"},{"key":"10.1016\/j.ando.2023.03.025_bib0225","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1210\/clinem\/dgaa032","article-title":"Daily oral administration of the novel androgen 11\u03b2-MNTDC markedly suppresses serum gonadotropins in healthy men","volume":"105","author":"Yuen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0230","doi-asserted-by":"crossref","first-page":"e2664","DOI":"10.1210\/clinem\/dgab129","article-title":"Serum insulin-like factor 3 levels are reduced in former androgen users, suggesting impaired leydig cell capacity","volume":"106","author":"Rasmussen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0235","doi-asserted-by":"crossref","first-page":"e2812","DOI":"10.1210\/clinem\/dgac194","article-title":"Reproductive phenotypes in men with acquired or congenital hypogonadotropic hypogonadism: a comparative study","volume":"107","author":"Maione","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0240","doi-asserted-by":"crossref","first-page":"E268","DOI":"10.1210\/jc.2013-2288","article-title":"Insulin-like peptide 3 (INSL3) in men with congenital hypogonadotropic hypogonadism\/Kallmann syndrome and effects of different modalities of hormonal treatment: a single-center study of 281 patients","volume":"99","author":"Trabado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0245","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1210\/er.2018-00116","article-title":"Clinical management of congenital hypogonadotropic hypogonadism","volume":"40","author":"Young","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2023.03.025_bib0250","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/EJE-21-0608","article-title":"Recovery of male reproductive endocrine function after ceasing prolonged testosterone undecanoate injections","volume":"186","author":"Handelsman","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2023.03.025_bib0255","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666141210222725","article-title":"Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review","volume":"13","author":"Piacentino","year":"2015","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.ando.2023.03.025_bib0260","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00213-015-4193-6","article-title":"Mad men, women and steroid cocktails: a review of the impact of sex and other factors on anabolic androgenic steroids effects on affective behaviors","volume":"233","author":"Onakomaiya","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.ando.2023.03.025_bib0265","doi-asserted-by":"crossref","first-page":"E292","DOI":"10.1210\/jc.2014-2658","article-title":"Sex steroids, precursors, and metabolite deficiencies in men with isolated hypogonadotropic hypogonadism and panhypopituitarism: a GCMS-based comparative study","volume":"100","author":"Giton","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0270","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1210\/jc.2016-3799","article-title":"Anti-m\u00fcllerian hormone and ovarian morphology in women with isolated hypogonadotropic hypogonadism\/kallmann syndrome: effects of recombinant human FSH","volume":"102","author":"Bry-Gauillard","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0275","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/GME.0000000000000093","article-title":"Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial","volume":"21","author":"Huang","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.ando.2023.03.025_bib0280","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mce.2017.07.010","article-title":"Do anabolic-androgenic steroids have performance-enhancing effects in female athletes?","volume":"464","author":"Huang","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ando.2023.03.025_bib0285","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000012362","article-title":"Psychiatric and medical effects of anabolicandrogenic steroid use in women","volume":"69","author":"Gruber","year":"2000","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.ando.2023.03.025_bib0290","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/JSM.0b013e3181fb5370","article-title":"Women and anabolic steroids: an analysis of a dozen users","volume":"20","author":"Ip","year":"2010","journal-title":"Clin J Sport Med"},{"key":"10.1016\/j.ando.2023.03.025_bib0295","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/dta.2689","article-title":"Detection of testosterone doping in female athletes","volume":"11","author":"Handelsman","year":"2019","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.ando.2023.03.025_bib0300","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1210\/er.2018-00020","article-title":"Circulating testosterone as the hormonal basis of sex differences in athletic performance","volume":"39","author":"Handelsman","year":"2018","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2023.03.025_bib0305","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/dta.186","article-title":"Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the cologne doping control laboratory 2009","volume":"2","author":"Kohler","year":"2010","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.ando.2023.03.025_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecl.2009.11.003","article-title":"Endogenous steroid profiling in the athlete biological passport","volume":"39","author":"Sottas","year":"2010","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ando.2023.03.025_bib0315","first-page":"dgad085","article-title":"Longitudinal profiling of endogenous steroids in blood using the athlete biological passport approach","author":"Equey","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0320","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1210\/clinem\/dgab799","article-title":"Application of the athlete biological passport approach to the detection of growth hormone doping","volume":"107","author":"Equey","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2023.03.025_bib0325","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.steroids.2010.04.007","article-title":"Analysis of anabolic steroids in human hair using LC-MS\/MS","volume":"75","author":"Deshmukh","year":"2010","journal-title":"Steroids"},{"key":"10.1016\/j.ando.2023.03.025_bib0330","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpba.2016.03.055","article-title":"Sports drug testing using complementary matrices: advantages and limitations","volume":"130","author":"Thevis","year":"2016","journal-title":"J Pharm Biomed Anal"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623000768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426623000768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:54:47Z","timestamp":1757717687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426623000768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0003426623000768"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2023.03.025","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doping with testosterone and androgenic\/anabolic steroids: Impact on health, screening tools and medical care","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2023.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}